Shrinking a Qidni

Morteza Ahmadi, CEO of Quidni labs, aims to design a small blood purification device that will offer longer treatment times and ultimately replace dialysis in clinics—at 40% less cost. With grants from programs including the Canadian Space Agency, the vision of Qidni is to “surpass current technology to become the new standard of treatment and help millions of patients on dialysis live a normal life.”

Read the full article » | Posted 03-16-2020

Related Articles

• The Lancet Digital Health published results of Humacyte’s Phase III clinical trial of its V007 acellular tissue engineered vessel (ATEV) HD access Posted 09-18-2026
• Humacyte, Inc. announced Robert J. Kossman, MD, FACP, FASN and Prabir Roy-Chaudhury, MD, PhD, FASN have joined the company as advisors. Posted 08-21-2026
• Byonyks on the Move: X-2 and X-3 APD Devices in Development Posted 07-16-2026
• Dr. Ben Reynolds and the Virtual Reality Kidney Dialysis Training Project Posted 06-17-2026